<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Respir J</journal-id><journal-id journal-id-type="iso-abbrev">Eur. Respir. J</journal-id><journal-id journal-id-type="publisher-id">ERJ</journal-id><journal-id journal-id-type="hwp">erj</journal-id><journal-title-group><journal-title>The European Respiratory Journal</journal-title></journal-title-group><issn pub-type="ppub">0903-1936</issn><issn pub-type="epub">1399-3003</issn><publisher><publisher-name>European Respiratory Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7144273</article-id><article-id pub-id-type="doi">10.1183/13993003.00858-2020</article-id><article-id pub-id-type="publisher-id">ERJ-00858-2020</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9965-6266</contrib-id><name><surname>Khoury</surname><given-names>Maroun</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cuenca</surname><given-names>Jimena</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cruz</surname><given-names>Fernanda F.</given-names></name><xref ref-type="aff" rid="af3">3</xref><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9387-094X</contrib-id><name><surname>Figueroa</surname><given-names>Fernando E.</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rocco</surname><given-names>Patricia R. M.</given-names></name><xref ref-type="aff" rid="af3">3</xref><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Weiss</surname><given-names>Daniel J.</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib></contrib-group><aff id="af1"><label>1</label>Laboratory of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Santiago, Chile</aff><aff id="af2"><label>2</label>Cells for Cells and consorcio Regenero, Chilean Consortium for Regenerative Medicine, Santiago, Chile</aff><aff id="af3"><label>3</label>Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil</aff><aff id="af4"><label>4</label>National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Brazil</aff><aff id="af5"><label>5</label>Department of Medicine, University of Vermont, Burlington, VT, USA</aff><author-notes><corresp id="cor1">Maroun Khoury, Division of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Av. La Plaza 2501, Las Condes, Chile. E-mail: <email>mkhoury@uandes.cl</email>, Daniel J. Weiss, Department of Medicine, University of Vermont, Burlington, VT USA. E-mail: <email>daniel.weiss@med.uvm.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>4</month><year>2020</year></pub-date><elocation-id>2000858</elocation-id><history><date date-type="received"><day>25</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>3</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9;ERS 2020</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="vor">http://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.</license-p></license></permissions><abstract><p>Severe respiratory consequences of the COVID-19 pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with the acute respiratory distress syndrome (ARDS), although not as yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (Influenza strains H5N1 and H9N2)-induced lung injury, however, there are no available data in models of coronavirus respiratory infection.</p><p>There are a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies, and targeted patient populations. To provide a rationale strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. These are presented along with consideration of current clinical investigations.</p></abstract><abstract abstract-type="short"><p>It is imperative to better comprehend the rationale and underlying data which both support and refute effectiveness of MSCs in respiratory virus infections, and to define the targeted patient population and potential cell therapy approaches for COVID-19.</p></abstract><funding-group><award-group id="funding-1"><funding-source><institution-wrap><institution>Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica
</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100002848</institution-id></institution-wrap></funding-source><award-id>FONDEF 2016, IT16I10084</award-id></award-group></funding-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The COVID-19 pandemic originating in Wuhan, China is rapidly and continuously spreading globally and can result in serious significant respiratory morbidity and mortality [<xref rid="C1" ref-type="bibr">1</xref>]. The responsible agent, SARS-CoV-2, is an enveloped RNA virus of the Coronaviridae virus family. Human-to-human transmission occurs through respiratory droplets or contaminated surfaces [<xref rid="C1" ref-type="bibr">1</xref>]. The average incubation period is 5&#x02005;days, but ranges from 1&#x02013;14&#x02005;days. Most patients present with mild respiratory tract infection, mostly commonly characterised by fever (82%) and cough (81%). Severe pneumonia and acute respiratory distress syndrome (ARDS) have been described in 14% of the reported cases, and the overall mortality is around 2% [<xref rid="C2" ref-type="bibr">2</xref>]. However, these numbers are in evolution as the pandemic spreads and depends on the country involved.</p><p>For COVID-19 patients who develop ARDS requiring intubation and mechanical ventilation, shock and multiple organ failure can also develop although whether this is a direct consequence of viral infection or complications of critical illness are not as yet clear. Current therapeutic approaches include aggressive standard supportive care and treatment of any other co-infections. Anti-viral medications including remdesivir, lopinavir&#x02013;ritonavir, or lopinavir&#x02013;ritonavir and interferon beta-1 are under investigation but safety and potential efficacy remains to be determined. Remdesivir and interferon beta-1&#x003b2; appear to have superior antiviral activity to lopinavir and remdesivir <italic>in vitro</italic> for the MERS coronavirus but whether this is the case for SARS-CoV-2 remains to be determined [<xref rid="C2" ref-type="bibr">2</xref>]. The FDA has recently approved use of hydroxychloroquine in COVID-19 patients but the efficacy remains to be determined. Growing information also suggests that virus-induced cytokine storm in the lungs may drive severe pathogenesis and provide potential therapeutic targets, for example anti-IL6 or anti-IL-1 approaches [<xref rid="C3" ref-type="bibr">3</xref>].</p><p>More recently, a growing number of clinical investigations of cell-based therapies, primarily involving mesenchymal stem (stromal) cells (MSCs), but also utilising MSC-derived conditioned media (CM) or extracellular vesicles (EVs) and several other cell types, have been initiated in China for COVID-19 respiratory disease. As these encompass a wide range of approaches and targeted patient groups, it is imperative to better understand the rationale and the potential mechanisms of MSC actions towards respiratory viral infections. Recent pre-clinical data in models of respiratory virus infections and relevant related clinical studies of MSC administration in patients with ARDS can contribute to better define the patient population towards whom potential MSC-based cell therapy approaches might be considered.</p></sec><sec id="s2"><title>Potential mechanisms of MSC actions in respiratory virus-induced lung injuries</title><p>Following systemic administration, the majority of MSCs lodge in the pulmonary vascular bed through as yet unclear interactions with the capillary endothelial cells. Tracking studies using labeled MSCs demonstrate the most are cleared within 24&#x02013;48&#x02005;h although there can be longer persistence in injured or inflamed lungs [<xref rid="C4" ref-type="bibr">4</xref>]. The clearance mechanisms are still being elucidated but include apoptosis and subsequent effereocytosis and phagocytosis by resident inflammatory and immune cells, notably macrophages [<xref rid="C5" ref-type="bibr">5</xref>]. While lodged in the lungs, the MSCs are able to release a wide variety of soluble mediators including anti-inflammatory cytokines [<xref rid="C6" ref-type="bibr">6</xref>], antimicrobial peptides [<xref rid="C7" ref-type="bibr">7</xref>], angiogenic growth factors, and extracellular vesicles (EVs) (<xref rid="F1" ref-type="fig">fig. 1</xref>) [<xref rid="C8" ref-type="bibr">8</xref>]. Direct cell-cell transmission of mitochondria from MSCs to respiratory epithelial and immune cells [<xref rid="C9" ref-type="bibr">9</xref>] has also been described [<xref rid="C10" ref-type="bibr">10</xref>]. A growing literature demonstrates that the pattern of anti-inflammatory mediators released is specific for the inflammatory lung environment encountered and is mediated through differential activation of damage and pathogen-associated molecular pathogen receptors expressed on MSC cell surfaces [<xref rid="C11" ref-type="bibr">11</xref>]. This includes toll-like receptors (TLRs) that are activated by viral RNA (TLR3) (as in COVID-19) and viral unmethylated CpG-DNA (TLR9), leading to downstream cell signaling pathways resulting in MSC activation [<xref rid="C12" ref-type="bibr">12</xref>]. MSC-secreted angiopoietin-1 (Ang-1) and keratinocyte growth factor (KGF) contribute to the restoration of alveolar-capillary barriers disrupted as part of ARDS pathogenesis [<xref rid="C13" ref-type="bibr">13</xref>] while specific inhibitory mRNAs (miRNAs) in EVs are also described as mediating the protective effects of MSCs in pre-clinical models of bacterial or non-infectious acute lung injuries [<xref rid="C14" ref-type="bibr">14</xref>]. However, mediators responsible for ameliorating respiratory viral-induced lung injuries remain unclear. In animal models, H9N2 viral infection increases serum and lung chemokines responsible for lung leukocyte infiltration, including Granulocyte-macrophage colony-stimulating factor (GMCSF), Monocyte chemoattractant protein-1 (MCP-1), Macrophage inflammatory protein-1 alpha (MIP-1&#x003b1;) and others that are markedly reduced by intravenous administration of MSCs [<xref rid="C15" ref-type="bibr">15</xref>]. Increased levels of interferon-gamma (IFN-&#x003b3;), typical of anti-viral immune responses, alone or together with other pro-inflammatory cytokines, prompt MSC activation including the release of anti-inflammatory mediators. The importance of such IFN &#x0201c;licensing&#x0201d; of immuno modulating effects has been previously demonstrated in a model of Graft <italic>versus</italic> Host Disease (GVHD), where the MSC treated recipients of IFN (&#x02212;/&#x02212;) T cell grafts, did not respond to cell therapy, evolving into fatal GVHD [<xref rid="C16" ref-type="bibr">16</xref>]. Unpublished data from COVID-19 patients in Italy suggest that high levels of IFN-&#x003b3; are found and thus may influence systemically administered MSCs (Massimo Dominici, personal communication). However, &#x0201c;licensed&#x0201d; MSCs can also suppress alloantigen-induced T cell functions <italic>in vitro</italic>, potentially compromising antiviral responses needed for disease control. For example, MSCs suppress lymphocyte proliferation in response to the activation of influenza-specific T cells <italic>in vitro</italic> [<xref rid="C17" ref-type="bibr">17</xref>]. Umbilical cord-derived MSCs (UC-MSCs) have also been shown to inhibit the cytotoxicity of specific T cells against H1N1 influenza virus <italic>in vitro</italic> [<xref rid="C18" ref-type="bibr">18</xref>], leading perhaps to prolonged infection in recipients. This is in contrast to reports where, for example, in models of CMV infection, MSCs exert differential effects on alloantigen and virus specific T cells that retain the ability to proliferate, produce IFN-&#x003b3;, and to kill CMV-infected cells <italic>in vitro</italic> [<xref rid="C19" ref-type="bibr">19</xref>].</p><fig id="F1" orientation="portrait" position="float"><label>FIGURE&#x000a0;1</label><caption><p>Potential therapeutic effects of MSCs in respiratory lung injury are mediated by different mechanisms including but not limited to secreted paracrine factors, extracellular vesicles (EVs), and possibly mitochondrial transfer, promoting tissue protection, immunomodulation, and possibly viral resistance. <?A3B2 tic=40%?>a)<?A3B2 tic?> Schematic of a healthy alveolus (top) and inflamed/edematous alveolus and mechanisms involved in ARDS pathogenesis; <?A3B2 tic=40%?>b)<?A3B2 tic?> Schematic of SARS-CoV-2 infecting lung epithelial cells with subsequent lysis and cytokine storm (middle left) and of potential MSC infection with unknown downstream consequences (middle right); <?A3B2 tic=40%?>c)<?A3B2 tic?> Some of the known mechanisms by which MSCs ameliorate non-viral acute lung injury (lower left); <?A3B2 tic=40%?>d)<?A3B2 tic?> Limited information on mechanisms by which MSCs might ameliorate SARS-CoV-2 lung damage based on limited pre-clinical data in influenza infection models (lower right). Figure adapted from Laffey and Matthay.<sup>1</sup>
<?A3B2 tic=40%?>e)<?A3B2 tic?> Current state-of-the-art of cell-based therapy in COVID-19, based on preclinical and clinical studies. Angiopoietin-1 (Ang1); keratinocyte growth factor (KGF); Hepatocyte growth factor (HGF); Macrophage-type 2 (M2 M&#x003a6;); Macrophage migration inhibitory Factor (MIF); Tumor Necrosis Factor-stimulated Gene-6 (TSG-6); Reactive oxygen species (ROS); Tumor Necrosis Factor alpha (TNF-a); Prostaglandin E2 (PGE2); Angiotensin converting enzyme 2 (ACE2); Interferon (IFN) stimulated genes (ISGs).</p></caption><graphic xlink:href="ERJ-00858-2020.01"/></fig><p>An important question that remains to be resolved in respiratory virus infections is whether protective MSC actions are directly against viral infection, perhaps by stimulating anti-viral T cells actions, or whether they are due to overall anti-inflammatory actions have been demonstrated in other models of acute lung injuries [<xref rid="C20" ref-type="bibr">20</xref>]. The latter may be particularly relevant for cytokine storm and it is likely that a combination of actions will be responsible.</p></sec><sec id="s3"><title>Effects of respiratory viruses on MSC actions</title><p>MSCs are generally resistant to viral infection compared to their differentiated progeny [<xref rid="C21" ref-type="bibr">21</xref>]. In part this reflects intrinsic expression of interferon (IFN) stimulated genes (ISG) that preempt viral infection [<xref rid="C21" ref-type="bibr">21</xref>]. MSC ISG expression includes, among others, IFITM (interferon-induced transmembrane family), IFI6, ISG15, SAT1, PMAIP1, p21/CDKN1A and CCL2. Among these antiviral proteins, members of the IFITM family members are unique as they prevent infection before a virus can traverse the lipid bilayer of the cell. These activities limit infection in cultured cells by many viruses, including dengue virus, Ebola virus, influenza A virus and SARS coronavirus [<xref rid="C22" ref-type="bibr">22</xref>]. Silencing of one of the most highly expressed ISGs in MSCs (p21/CDKN1A), specifically increased their susceptibility to chikungunya virus (CHIKV), whereas knockdown of IFITM3 rendered MSC susceptible to infection by a variety of viruses including YFV and ZIKV [<xref rid="C21" ref-type="bibr">21</xref>].</p><p>Utilizing RNAseq (GSE97987) and validated by qRT-PCR [<xref rid="C21" ref-type="bibr">21</xref>], we established a list of ISGs constitutively expressed by human embryonic stem cell derived-MSCs. Bioinformatic analysis of 5 independent GEO databases for expression changes following different pro-inflammatory cytokine stimulation of intrinsic ISGs in human MSCs (3 BM-MSC, 1 UC-MSC, 1 AD-MSC, with the respective GEO data set of GSE68610, GSE77814, GSE46019, GSE46019 and GSE18662) (<xref rid="F2" ref-type="fig">fig. 2</xref>). demonstrated that pro-inflammatory cytokines including IFN-&#x003b3; induced non-constitutive ISGs includingMT1X, MT1G, SERPING1, SAT1, IFNAR2, CD74, while significantly increasing the expression of constitutive antiviral genes such as: IFI6, ISG15, CCL2, SAT1, PMAIP1 and IFITM1.
</p><fig id="F2" orientation="portrait" position="float"><label>FIGURE&#x000a0;2</label><caption><p>Representative volcano plots analysis of gene expression of the interferon (IFN) stimulated genes (ISGs) in human BM-MSC activated with proinflammatory cytokines (IL1&#x003b2;, TNF-&#x003b1; and IFN-&#x003b3;), GSE68610. <?A3B2 tic=40%?>a)<?A3B2 tic?> Gene expression analysis of constitutive and <?A3B2 tic=40%?>(b)<?A3B2 tic?> non-constitutive ISGs. Interferon-induced transmembrane protein (IFITIM); metalloproteinase inhibitor 1 (TIMP-1); Plasminogen activator inhibitor 1(SERPINE1); Interferon alpha-inducible protein 6 (IFI6); Ubiquitinlike protein (ISG15); sulfate anion transporter 1 (SAT1); Cytochrome p450 1b1 (CYP1B1); Neuronal pas domain-containing protein 2 (NPAS2); Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1); c-c motif chemokine 2 (CCL2); Frizzled-5 (FZD-5); Ornithine decarboxylase 1 (ODC1); Monocarboxylate transporter 1 (SLC16A1); Interferon alpha/beta receptor 2 (IFNAR2); Plasma Protease C1 Inhibitor (SERPING1); Metallothionein 1G/X (MT1G/ MT1X).</p></caption><graphic xlink:href="ERJ-00858-2020.02"/></fig><p>Hence, in the context of a respiratory viral infection, including COVID-19, MSCs might present two distinct antiviral mechanisms: constitutively elevated levels of MSC-specific ISGs to function as mediators of an antiviral protection, and a secondary response to IFN, leading to ISG induction and broad viral resistance. Conversely, MSCs could present a mix of intrinsic and inducible innate antiviral defenses that could lead to therapeutic benefits in COVID-19 patients.</p><p>In contrast, some literature demonstrates that human BM-MSCs are permissive to avian influenza A (H5N1) infection, losing viability and immunoregulatory activities [<xref rid="C15" ref-type="bibr">15</xref>]. This can occur rapidly following exposure of uninfected MSCs [<xref rid="C23" ref-type="bibr">23</xref>] and virus-infected MSCs may thus not be functionally effective at stopping virus replication and lung inflammation [<xref rid="C24" ref-type="bibr">24</xref>&#x02013;<xref rid="C27" ref-type="bibr">27</xref>]. BM-MSCs express influenza virus alpha-2,3 and alpha-2,6 sialic acid receptors on their cell surfaces and can support replication of both avian H1N1 and H9N5 influenza strains [<xref rid="C24" ref-type="bibr">24</xref>, <xref rid="C25" ref-type="bibr">25</xref>]. Influenza-infected MSCs undergo cell lysis apoptosis within 18&#x02005;h post -exposure, with corresponding production of pro-inflammatory cytokines and chemokines [<xref rid="C24" ref-type="bibr">24</xref>] potentially subverting their protective immunomodulatory properties [<xref rid="C26" ref-type="bibr">26</xref>]. The respiratory syncytial virus (RSV) can also infect MSCs modifying immune cell proliferation and activity [<xref rid="C27" ref-type="bibr">27</xref>]. As such, depending on the virus type and the level of expression or percentage of MSCs expressing the virus receptor, MSCs may get infected if infused into a patient with an ongoing respiratory virus infection. How this would affect potential beneficial effects remains to be determined.</p></sec><sec id="s4"><title>Do MSCs express ACE2, the functional receptor of SARS-CoV-2?</title><p>Angiotensin-converting enzyme 2 (ACE2) has been reported to be the main host cell receptor of the SARS-COv-2 entry and the serine protease TMPRSS2 for S protein priming [<xref rid="C28" ref-type="bibr">28</xref>]. ACE2 is highly expressed in respiratory epithelial cells thus playing a crucial role in the entry of virus into these cells [<xref rid="C29" ref-type="bibr">29</xref>]. ACE2 was recently also demonstrated to be an ISG in nasal epithelial cells [<xref rid="C30" ref-type="bibr">30</xref>]. Hence, SARS-CoV-2 may exploit IFN-driven upregulation of ACE2, a key tissue-protective mediator during lung injury, to enhance infection. Conversely, ACE2 was reported to protect against non-viral lung injury by degrading the profibrotic peptide angiotensin (Ang) II [<xref rid="C31" ref-type="bibr">31</xref>]. <italic>In vivo</italic> gene silencing of ACE2 enhances bleomycin-induced lung collagen deposition in mice, whereas systemic administration of purified ACE2 inhibits the fibrotic response [<xref rid="C32" ref-type="bibr">32</xref>]. Murine BM-MSCs over-expressing the ACE2 gene following lentiviral vector transduction, offered additional anti-inflammatory and endothelial-protective effects against endotoxin-induced lung injury in mice [<xref rid="C33" ref-type="bibr">33</xref>, <xref rid="C34" ref-type="bibr">34</xref>], However, there may be a downside to this if ACE2 over-expression results in infection and subsequent deleterious effects on the MSCs. As the level of gene expression is a key determinant of SARS-CoV-2 transmissibility [<xref rid="C28" ref-type="bibr">28</xref>], it is relevant to assess whether MSCs of any origin constitutively or inducibly express ACE2 or TMPRSS2.</p></sec><sec id="s5"><title>MSCs in respiratory virus-related lung injury: Pre-clinical evidence</title><p>There is a large literature demonstrating efficacy of either systemic or direct intratracheal MSC administration in pre-clinical models of respiratory diseases including those involving acute lung injury induced by bacterial or bacterial products (endotoxin) or other means [<xref rid="C35" ref-type="bibr">35</xref>]. The models include both rodents as well as large animal (pig, sheep) and explanted human lungs. A range of approaches have been utilised for dose, dosing, and MSC source with MSCs of bone marrow (BM), adipose, umbilical cord, cord blood, and placenta being investigated . A recent systematic review indicated that BM and UC-MSCs were more effective than adipose tissue derived MSCs in reducing mortality in pre-clinical acute lung injury models [<xref rid="C36" ref-type="bibr">36</xref>].</p><p>However, there are only a small number of pre-clinical studies investigating effects of MSC administration in pre-clinical models of respiratory virus infections. These have further been limited to influenza viruses, have produced conflicting results, and have not as yet directly addressed coronavirus respiratory infections (<xref rid="TB1" ref-type="table">table 1</xref>). Notably two earlier studies found MSCs not to be protective against influenza respiratory infections in mice. Darwish and colleagues assessed the effects of a single systemic administration in immunocompetent mice of either syngeneic murine bone marrow-derived MSCs or xenogeneic human bone marrow-derived MSCs on lung injury induced by mouse-adapted H1N1 or swine-origin pandemic H1N1 [<xref rid="C37" ref-type="bibr">37</xref>]. Two different doses of MSCs (2.5 or 5&#x000d7;10<sup>5</sup> cells/mouse) were administered at different time points after virus administration: Day &#x02212;2, 0, 2 and 5 post-infection (p.i.). Using survival and different measures of lung inflammation as outcome endpoints on day 7 p.i., neither syngeneic or xenogeneic MSC administration, either alone or as an adjuvant therapy with oseltamivir, was effective either when administered prophylactically, prior to virus inoculation, or when therapeutically administered. Similarly, Gotts and colleagues assessed the effect of both systemic and intratracheal administration of human and mouse MSCs (5&#x000d7;10<sup>5</sup> cells/mouse), administered in two doses, either earlier (day 2 and 3 p.i.) or later (day 5 and 6 p.i.), in mouse adapted H1N1-induced lung injury in immunocompetent mice [<xref rid="C38" ref-type="bibr">38</xref>]. However, MSCs did not improve influenza-mediated lung injury regardless of administration route.
</p><table-wrap id="TB1" orientation="portrait" position="float"><label>TABLE&#x000a0;1</label><caption><p>Preclinical studies: MSCs in respiratory virus-related lung injury</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><bold>Reference</bold></td><td align="left" rowspan="1" colspan="1"><bold>Experimental model, route of infection, type of virus</bold></td><td align="left" rowspan="1" colspan="1"><bold>MSC source, passage, number, administration route, timing of treatment</bold></td><td align="left" rowspan="1" colspan="1"><bold>Time of outcome analysis</bold></td><td align="left" rowspan="1" colspan="1"><bold>Adjuvant therapy</bold></td><td align="left" rowspan="1" colspan="1"><bold>Outcome</bold></td><td align="left" rowspan="1" colspan="1"><bold>Mechanisms of action</bold></td><td align="left" rowspan="1" colspan="1"><bold>Control Group</bold></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Darwish <italic>et al</italic>., 2013</bold></td><td align="left" rowspan="1" colspan="1">C57BL/6 mice 7&#x02013;10&#x02005;weeks IN infection Influenza A/PuertoRico/8/34 (mouse- adapted H1N1) or Influenza A/Mexico/410 8/2009 (swine-origin pandemic H1N1)</td><td align="left" rowspan="1" colspan="1">Mouse BM -MSCs (P6-P9)<break/>Human BM &#x02013; MSCs (P3)<break/>2.5&#x000d7;10<sup>5</sup> cells 5&#x000d7;10<sup>5</sup> cells IV (tail vein) Single dose<break/>Day &#x02212;2, 0, 2, 5 post infection</td><td align="left" rowspan="1" colspan="1">Day 7 or when euthanasia criteria was met</td><td align="left" rowspan="1" colspan="1">Oseltamivir<break/>2.5&#x02005;mg&#x000b7;kg<sup>&#x02212;1</sup> Oral gavage<break/>Once daily 5&#x02005;days</td><td align="left" rowspan="1" colspan="1">Prophylatic and therapeutic syngeneic and xenogeneic administration of MSCs:<break/>Failed to improve survival,<break/>Failed to affect weight loss, and<break/>Failed to decrease lung parenchyma inflammation and BALF cell counts.</td><td align="left" rowspan="1" colspan="1">Non-specified (soluble mediators)</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gotts et al., 2014</bold></td><td align="left" rowspan="1" colspan="1">C57BL/6 mice 7&#x02013;10&#x02005;weeks IN infection Influenza<break/>A/Puerto Rico/8/34 (mouse-adapted H1N1)</td><td align="left" rowspan="1" colspan="1">Mouse BM&#x02013;MSCs (P7 or less) Human BM&#x02013; MSCs (P7 or less) 5&#x000d7;105&#x000a0;cells<break/>IV (Retro-orbital injection)<break/>IT (Data not shown) Two doses Either:<break/>Day 5 and 6 post infection, or<break/>Day 2 and 3 post infection (data not shown)</td><td align="left" rowspan="1" colspan="1">Days 7, 9 or 11</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Mouse MSCs: Prevented influenza- induced thrombocytosis, Caused a modest reduction in lung viral load on <italic>day 7</italic>,<break/>Early (data not shown) and late syngeneic and<break/>xenogeneic intravenous administration of MSCs: Failed to affect weight loss.<break/>Failed to decrease lung water.<break/>Failed to decrease BALF inflammation, and Failed to improve lung histology<break/>Intratracheal administration increased the severity of model data not shown).</td><td align="left" rowspan="1" colspan="1">Non-specified (soluble mediators)</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Chan, 2016</bold></td><td align="left" rowspan="1" colspan="1">BALB/c mice<break/>6&#x02013;8&#x02005;weeks -<break/>young<break/>8&#x02013;12&#x02005;months &#x02013; old<break/>IN infection with<break/>Influenza A<break/>/Hong<break/>Kong/486/199<break/>7(H5N1)</td><td align="left" rowspan="1" colspan="1">Human BM&#x02013;<break/>MSCs (Passage<break/>not mentioned) 5&#x000d7;105 cells IV<break/>Single dose<break/>Day 5 post<break/>infection</td><td align="left" rowspan="1" colspan="1">Days 7, 10 or 18</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">In aged mice, but not young mice, allogeneic MSCs:<break/>Increased survival, Reduced weight loss, Reduced lung histopathological lesions, Increased M2 macrophages in BALF, Reduced lung proinflammatory cytokines and chemokines (MCP-1, MCP-3, MIP-1 &#x003b1;, RANTES, IL-4, IL-17, TNF-&#x003b1;), and Reduced lung virus titers</td><td align="left" rowspan="1" colspan="1">Paracrine soluble mediators, partially due to Ang1 and KGF secretion</td><td align="left" rowspan="1" colspan="1">NIH 3T3 mouse embryo fibroblasts</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Li <italic>et al</italic>., 2016</bold></td><td align="left" rowspan="1" colspan="1">C57BL/6 mice 6&#x02013;8&#x02005;weeks<break/>IN infection with Avian<break/>Influenza virus Hong Kong/2108/20 03 (H9N2)</td><td align="left" rowspan="1" colspan="1">Mouse BM-MSCs (P3-P10)<break/>1&#x000d7;105 cells IV (tail vein) Single dose<break/>30&#x02005;min, or Day 1 post-infection</td><td align="left" rowspan="1" colspan="1">Day 3</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Regardless of time administration, syngeneic MSCs:<break/>Did not reduce lung virus titration,<break/>Increased survival rate, Decreased lung edema, Decreased histologic injury,<break/>Improved gas exchange, Reduced BALF chemokines and cytokines<break/>early administration: GM-CSF, MIG content, IL-1&#x003b1;, IFN-&#x003b3;, IL-6, TNF-<break/>&#x003b1;,<break/>Reduced serum chemokines and cytokines<break/>early administration: MIG content, IL-1&#x003b1;, IFN- &#x003b3;, IL-6, TNF- &#x003b1;,<break/>Early administration increased anti- inflammatory cytokine IL-10 in BALF and<break/>serum.</td><td align="left" rowspan="1" colspan="1">Non-specified (soluble mediators)</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Khatri <italic>et al</italic>., 2016</bold></td><td align="left" rowspan="1" colspan="1">White-Duroc crossbred pigs 8&#x02005;weeks<break/>IN infection with Swine/TX/98 Influenza virus<break/>- H3N2 and Swine/MN/08 (H1N1)</td><td align="left" rowspan="1" colspan="1">Pig BM-MSCs EVs (P3-P5)<break/>80&#x02005;&#x003bc;g&#x000b7;kg<sup>&#x02212;1</sup><break/>body weight (produced by 10&#x000d7;106&#x000a0;MSCs) IT<break/>Single dose 12&#x02005;h post- infection</td><td align="left" rowspan="1" colspan="1">Days 1 or 3</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">BM-MSC-derived EVs: Decreased virus shedding in nasal swabs,<break/>Reduced influenza virus replication in the lungs,<break/>Prevent virus-induced production of pro- inflammatory cytokines (TNF-&#x003b1;, CXCL-10),<break/>Reduced histologic injury and lung edema.</td><td align="left" rowspan="1" colspan="1">Non-specified (extracellular vesicles)</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Loy <italic>et al</italic>., 2019</bold></td><td align="left" rowspan="1" colspan="1">BALB/c mice<break/>6&#x02013;8&#x02005;weeks<break/>IN infection with Influenza A/Hong<break/>Kong/486/1997 (H5N1)</td><td align="left" rowspan="1" colspan="1">Human UC&#x02013;MSCs (P7 or less) 5&#x000d7;105&#x000a0;cells IV<break/>Single dose Day 5 post infection</td><td align="left" rowspan="1" colspan="1">Days 7, 10,<break/>14 or 18</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">UC-MSCs<break/>Failed to decrease lung virus titration,<break/>Failed to increase survival rate,<break/>Reduced body weight loss,<break/>Decreased lung edema, and<break/>Decreased BAL cytokines (IP-10, MCP-1, RANTES, IL-1&#x003b2;.</td><td align="left" rowspan="1" colspan="1">Paracrine soluble mediators, partially due to Ang1 and HGF secretion</td><td align="left" rowspan="1" colspan="1">NIH 3T3 mouse embryo fibroblasts</td></tr></tbody></table><table-wrap-foot><p>Preclinical studies showing the effects of MSCs in virus-mediated lung injury. ALI: acute lung injury; Ang1: angiopoietin 1; BM: MSCs: bone marrow-derived mesenchymal stem (stromal) cells; CXCL-10: C-X-C motif chemokine; EV: extracellular vesicles; GM-CSF: granulocyte-macrophage colony-stimulating fator; IL:Interleukin; IN: Intranasal; IT: intratracheal; IP-10: interferon &#x003b3;&#x02013; induced protein 10; IV: Intravenous; MCP: monocyte chemoattractant; MIG: monokine induced by interferon-&#x003b3; ; MIP: macrophage inflammatory protein; RANTES: Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted; TNF: Tumor necrosis factor; UC-MSCs: umbilical cord-derived MSCs.</p></table-wrap-foot></table-wrap><p>In contrast, more recent studies have demonstrated protective effects of systemic MSC administration in rodent and pig models of influenza respiratory infections. Chan and colleagues found in <italic>in vitro</italic> assays that MSCs improved the dysregulated alveolar fluid clearance and protein permeability induced by H5N1 and H7N9 influenza viruses, in part by releasing soluble mediators that up-regulated sodium and chloride transporters. Systemic administration of 5&#x000d7;10<sup>5</sup> human bone-marrow derived MSCs/mouse on day 5 p.i. in aged (8&#x02013;12&#x02005;months) immunocompetent mice infected with Influenza A (H5N1) [<xref rid="C39" ref-type="bibr">39</xref>] reduced virus-induced mortality (until day 18 p.i.), weight loss (day 6&#x02013;10 p.i.), lung edema (day 7 p.i.), BALF CD4+ T and natural killer (NK) cells (day 7 p.i.), lung histopathological lesions (day 18 p.i.), pro-inflammatory cytokines and chemokines (day 7 p.i.) without reducing lung virus titers (day 7 and 10 p.i.). They further found that Ang-1 and KGF released by MSCs were important, but not enough to attenuate the effects of viral infection on alveolar fluid clearance and permeability. However, in young (6&#x02013;8&#x02005;weeks) mice, no effects were observed in mortality and body weight loss. Thus, the data suggests that systemic MSC administration may provide benefit in older patients who are at higher risk for severe pulmonary illness caused by H5N1. Why this was less effective in younger mice is not clear at present.</p><p>Li and colleagues investigated the impact of low dose (10<sup>5</sup> cells/mouse) of murine bone marrow-derived MSCs in Avian Influenza virus (H9N2)-induced lung injury in young immunocompetent mice [<xref rid="C15" ref-type="bibr">15</xref>]. A single intravenous administration led on day 3 p.i. to reduction in mortality, lung edema, histologic injury, bronchoalveolar lavage fluid (BALF) and serum chemokines and cytokines, as well as improving gas-exchange and levels of anti-inflammatory mediators, although not reducing lung virus titration when administered either 30&#x02005;min or 24&#x02005;h after infection induction. Differences between early and later administration of MSCs were only observed in some BALF and serum inflammatory mediators. Only early administration reduced BALF monokine induced by interferon-&#x003b3; (MIG), GM-CSF; BALF and serum interleukin 1-&#x003b1; and interferon-&#x003b3;; and increased levels of BALF and serum IL-10. Both early and later administration led to reduction of BALF and serum IL-6 and TNF-&#x003b1;. This might reflect that early administration seems more geared towards prevention of cell infection and inflammation, rather than dealing with more clinically relevant sequelae of epithelial infection. Avian influenza virus infection can trigger a very intense pro-inflammatory response compared to other influenza viruses; thus, authors speculated that the beneficial effects might be a specific consequence of different pathogenic features as compared to swine origin H1N1 infection [<xref rid="C15" ref-type="bibr">15</xref>].</p><p>Loy and colleagues found that UC-MSCs were more effective than human BM-derived MSCs (BM-MSCs) at restoring impaired alveolar fluid clearance and permeability <italic>in vitro</italic> airway epithelial cell models [<xref rid="C40" ref-type="bibr">40</xref>]. These effects were partially mediated through MSC secretion of Ang-1 and hepatocyte growth factor (HGF). The authors subsequently compared administration of UC-MSCs to BM-MSCs (5&#x000d7;10<sup>5</sup> cells/mouse, day 5 p.i.) in experimental lung injury induced by Influenza A (H5N1) infection in female 6&#x02013;8 week old immunocompetent mice. Despite failure to reduce virus titer and increase survival rate, a single dose of UC-MSCs decreased body weight loss (days 16, 17 p.i.), lung edema (days 10, 14 p.i.), and inflammation in H5N1-induced lung injury (day 7 p.i.).</p><p>.</p><p>MSCs-derived EVs have been demonstrated to have comparable and in some cases more effective than MSCs themselves in ameliorating inflammation and injury in a range of pre-clinical lung injury models [<xref rid="C41" ref-type="bibr">41</xref>, <xref rid="C42" ref-type="bibr">42</xref>]. Khatri and colleagues found that systemic administration of EVs isolated from pig bone marrow-derived MSCs was safe and reduced virus shedding in nasal swabs, influenza replication in the lungs, BALF pro-inflammatory cytokines and chemokines, histopathological changes when administered 12&#x02005;h after viral inoculation in a mixed swine (H3N2, H1N1) and avian (H9N5, H7N2) influenza-induced pig lung injury model [<xref rid="C43" ref-type="bibr">43</xref>]. These findings suggest systemic EV administration as a potential cell-free strategy for use in respiratory virus-induced lung injuires.</p><p>There are as yet no pre-clinical data investigating effects of MSC administration in models of coronavirus respiratory infection, mostly due to the lack of an established animal model. SARS-CoV-2 replication was observed in several non-human primate and in inbred strains of mice following intranasal infection, but these models failed to show clinical signs of pulmonary disease as seen in human [<xref rid="C44" ref-type="bibr">44</xref>]. hACE2 transgenic mice infected with SARS-CoV-2 demonstrated virus replication in lung and interstitial pneumonia with lymphocyte and monocytes infiltration into the alveolar interstitium and accumulation of macrophages in alveolar spaces [<xref rid="C45" ref-type="bibr">45</xref>]. While this model requires further evaluation it might facilitate the testing of therapeutics including cell-based therapies for COVID-19. Recently, a non-human primate model for SARS-CoV-2 was able to reflect the same clinical signs, viral replication, and pathology observed in humans with comparable levels of mortality and might be a valuable model for further evaluation [<xref rid="C46" ref-type="bibr">46</xref>].</p><p>Overall, it remains unclear whether the varying results reflect differing features of each approach including the host (age), MSCs (source, number, route of administration), and different virus-specific inflammatory patterns. Infection of the administered MSCs by the viruses, particularly the Avian influenza viruses, might explain the lack of effectiveness observed in some <italic>in vivo</italic> studies, but MSC infection after their administration <italic>in vivo</italic> has not yet been investigated. In order to bypass the impact of viruses on MSCs, EVs might be an option for further studies. Clearly, further pre-clinical studies must be done evaluating the infectiveness of MSCs by coronaviruses and the impact of MSCs in coronavirus-induced lung injury models.</p></sec><sec id="s6"><title>Clinical investigations of MSC administration in patients with coronavirus or other respiratory virus induced lung injury</title><p>Despite suggestive recent evidence of potential efficacy of MSC administration in pre-clinical models of influenza respiratory viral lung infections, there are limited published clinical data available. A just published single center open-label pilot investigation from the YouAn Hospital in Beijing administered BM-derived MSCs to seven patients with COVID-19 pneumonia with differing degrees of severity including one patient with critically severe disease requiring ICU care [<xref rid="C47" ref-type="bibr">47</xref>]. The MSCs were given as a single intravenous administration at a dose of 10<sup>6</sup>&#x02005;cells&#x000b7;kg<sup>&#x02212;1</sup> body weight in 100&#x02005; mL saline at various times after initial symptomatic presentation. The MSCs were assessed by RNAseq for expression of ACE2 or TMPRSS2 prior to administration and each was found to be minimally expressed (1/12&#x0200a;500 cells and 7/12&#x0200a;500 cells, respectively) although the RNAseq results were not validated for gene (qRT-PCR) or protein expression.</p><p>The seven patients were categorised as critically severe (n=1), severe (n=4), and common type (n=2). Three additional patients classified as severe received placebo (vehicle) administration for comparison. Patients were followed for 14&#x02005;days after MSC or placebo administration and a range of safety and efficacy endpoints were assessed. No infusional toxicities, allergic reactions, secondary infections, or severe attributable adverse events were observed and patients, including the one categorised as critically severe, apparently demonstrated clinical improvements within 2&#x02013;4&#x02005;days after MSC administration However, while detailed information is provided for the critically severe patient, there is a lack of corresponding information for the other 6 patients or for the three placebo patients. Comparably, analyses of viral titers, circulating pro- and anti-inflammatory mediators, and lymphocyte numbers and populations were presented in detail for the critically severe patient and to a lesser degree for the other patients.</p><p>As such, more detailed information as to inclusion and exclusion criteria, timing of MSC administration relative to onset of disease, co-morbidities, clinical course of each patient, and evaluation of inflammatory mediators and cell populations for both treated and placebo patients are needed to better determine potential MSC efficacy and mechanisms of action. Importantly, there is no discussion as to whether the approach be further investigated in only critically severe and/or severe patients or for the broader range of clinical presentations of COVID-19 respiratory infection.</p><p>A second recently published study evaluated MSC administration in patients with H7N9 influenza virus respiratory infections during the 2013&#x02013;2014 outbreak in China [<xref rid="C48" ref-type="bibr">48</xref>]. In this study, 17 critically-ill patients with H7N9-induced ARDS received multiple IV administrations of menstrual blood-derived cells (10<sup>6</sup> cells/infusion in Plasmalyte) obtained from a single healthy donor and outcomes were compared to 44 comparably critically ill patients receiving standard antiviral and supportive therapies. Of the treated patients, 3 are described as receiving 3 separate infusions during early stage infection, 6 patients received 3 infusions at late stage infection and 8 patients received 4 infusions at late stage infection. However, no information is provided concerning the timing between infusions or whether the control patients received vehicle infusions. The MSC-treated and control patients were otherwise fairly well matched for comorbidities and degrees of multi-organ failure and use of other supportive therapies except for a higher incidence of shock in the MSC-treated group (p&#x0003c;0.03). No apparent infusional toxicities or serious adverse events were noted. 3 patients in the MSC-treated group died (82.4% survival) whereas 24 in the control died (45.5% survival). However, no details on the deaths, including cause and timing related to either infusion or to overall clinical course, or on other standard assessments including ventilator-free days, ICU stay, or hospital stay, were provided. Complete blood count and measures of renal, liver, cardiac, and coagulation functions were comparable except for a higher circulating pro-calcitonin level in the control group, perhaps suggestive of secondary or co-bacterial infections although no information on other infections was provided. The authors concluded that MSC administration is a viable approach for H7N9-induced ARDS and that this could be potentially applicable to use in COVID-19 patients.</p><p>These two studies, while suggestive, highlight a number of issues with respect to potential use of MSCs in coronavirus and other viral respiratory infections. These include but are not limited to source of MSCs, dose, and dosing strategies including the number and timing of administrations. These studies also highlight issues with conduct of clinical trials for respiratory diseases including those in critically ill patients. Full information about inclusion and exclusion criteria, clinical course, co-morbidities, co-infections, and laboratory evaluations, including investigative mechanistic evaluations, must be provided in a comprehensive manner.</p></sec><sec id="s7"><title>Assessment of the ongoing cell-based clinical trials registered during the outbreak</title><p>At the time of this review, the number of cell-based clinical investigations to explore the therapeutic potential of cell treatment for SARS-CoV-2 infected patients registered since late January on the NIH clinicaltrials.gov and the Chinese Clinical Trial Registry (chictr.org.cn) also accessible from the World Health Organization-International Clinical Trial Registry Platform (WHO-ICTRP) has reached 27 entries with a total of approximately 1287 patients considered for enrollement (<xref rid="TB2" ref-type="table">table 2</xref>). There are three main interventions: MSCs (n=17, 781patients), MSC derivatives (CM, EVs, n=4, 176 patients), or other cell sources (n=6, 330 patients). General common features of the investigations include a) systemic administration, jointly or followed by the recommended conventional supportive treatments for severe or critical SARS-CoV-2 infection; [<xref rid="C49" ref-type="bibr">49</xref>] b) age range 18&#x02013;80&#x02005;years old with no gender restrictions; c) follow up for at least three months; and d) clinical samples collected will be throat secretions and/or blood. For the MSC investigations, 9/17 will utilise UC-MSCs, 1/17 will utilise menstrual blood-origin MSCs, and 6/17 do not disclose the MSC tissue source. Notably, no apparent MSCs of bone marrow origin are being utilised despite the majority of pre-clinical investigations for non-viral induced acute lung injuries having utilised BM-MSCs. There was little clarification of use of cryopreserved <italic>versus</italic> continuously cultured cells [<xref rid="C5" ref-type="bibr">5</xref>]. Only 6/16 disclosed the intended cell injection dose, among which only 4 were correlated with the patient body weight. The intravenous dosing range varies between 0.4 and 42&#x000d7;10<sup>6</sup>&#x02005;cells&#x000b7;/kg<sup>&#x02212;1</sup>. In comparison, the highest dose of MSCs used in the published literature for clinical trials in non-viral ARDS was 10&#x000d7;10<sup>6</sup>&#x02005;cells&#x000b7;kg<sup>&#x02212;1</sup> (START trial) [<xref rid="C50" ref-type="bibr">50</xref>]. The dosing strategy ranged between a single and 5 doses with an average frequency of every 2&#x02005;days.
</p><table-wrap id="TB2" orientation="portrait" position="float"><label>TABLE&#x000a0;2</label><caption><p>Cell-based clinical trials ( MSC, MSC derivatives and other cells)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><td align="left" colspan="7" rowspan="1"><bold>Clinical trials based on MSCs</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>Date of registration/ Execution time</bold></td><td align="left" rowspan="1" colspan="1"><bold>Study phase/Recruitment status</bold></td><td align="left" rowspan="1" colspan="1"><bold>ID/URL</bold></td><td align="left" rowspan="1" colspan="1"><bold>Title</bold></td><td align="left" rowspan="1" colspan="1"><bold>Cell type</bold></td><td align="left" rowspan="1" colspan="1"><bold>Number of total particpants/ Intervention or treatment</bold></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>1</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">14&#x02013;02-2020/20-02-2020 to 20-02-2021</td><td align="left" rowspan="1" colspan="1">0/Not Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000029816<ext-link ext-link-type="uri" xlink:href="/http://www.chictr.org.cn/">/http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=49389</td><td align="left" rowspan="1" colspan="1">Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID- 19)</td><td align="left" rowspan="1" colspan="1">UCB- MSCs; UCB-NK</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Conventional treatment followed by iv infusion UCB- MSCs<break/>Control group: Conventional treatment</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>2</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">14-02-2020/20-02-2020 to 20-02-2021</td><td align="left" rowspan="1" colspan="1">0/ Not Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000029817/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=49384</td><td align="left" rowspan="1" colspan="1">Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID- 19)</td><td align="left" rowspan="1" colspan="1">NK and UCB- MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group:High dose group: High-dose NK cells (&#x0003e;5&#x000d7;10<sup>9</sup>) and MSCs (&#x0003e;5&#x000d7;10<sup>9</sup>), iv infusion once, every 2 days for a total of 5 times<break/>Conventional dose group:<break/>Conventional dose NK cells (&#x0003e;3&#x000d7;10<sup>9</sup>) and MSCs (&#x0003e;3&#x000d7;10<sup>9</sup>), iv infusion once every 2 days for a total of 3 times Preventive dose group:<break/>Preventive dose NK cells (&#x0003e;3&#x000d7;10<sup>9</sup>) and MSCs (&#x0003e;3&#x000d7;10<sup>9</sup>), iv infusion once every week for a total of 1<break/>time.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>3</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">63</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">07-02-2020/15-01-2020 to 31-12-2022</td><td align="left" rowspan="1" colspan="1">0/ Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000029606/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=49146</td><td align="left" rowspan="1" colspan="1">Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)</td><td align="left" rowspan="1" colspan="1">MenSCs</td><td align="left" rowspan="1" colspan="1">Experimental group A:<break/>1. Conventional treatment followed by iv infusion of MenSCs. Control group A:<break/>Conventional treatment<break/>Experimental group B:<break/>1: Artificial liver therapy+conventional treatment<break/>2: Artificial liver therapy followed by iv infusion of MenSCs +conventional treatment Control group A: Conventional treatment</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>4</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">07-02-2020/06-02-2020 to 30-09-2020</td><td align="left" rowspan="1" colspan="1">2/ Recruiting</td><td align="left" rowspan="1" colspan="1">NCT04269525/<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> show/NCT04269525</td><td align="left" rowspan="1" colspan="1">Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia</td><td align="left" rowspan="1" colspan="1">UC- MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>UC-MSCs 3.3&#x000d7;107 cells/50&#x02005;mL/bag, 3 bags each time. And UC-MSCs will be infused iv on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day. Control group: None specified</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>5</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">70</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">05-02-2020/31-01-2020 to 31-12-2020</td><td align="left" rowspan="1" colspan="1">0/ Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000029580/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=49088</td><td align="left" rowspan="1" colspan="1">A prospective, single-blind, randomized controlled trial for Ruxolitinib combined with mesenchymal stem cell infusion in the treatment of patients with severe 2019-nCoV pneumonia<break/>(novel coronavirus pneumonia, NCP)</td><td align="left" rowspan="1" colspan="1">MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Ruxolitinib combined with MSCs.<break/>Control group: Routine treatment.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>6</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">27-01-2020/21-01-2020 to 00-12 2021</td><td align="left" rowspan="1" colspan="1">1/Recruiting</td><td align="left" rowspan="1" colspan="1">NCT04252118/<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> show/NCT04252118</td><td align="left" rowspan="1" colspan="1">Mesenchymal Stem Cell<break/>Treatment for Pneumonia Patients<break/>Infected With 2019 Novel Coronavirus</td><td align="left" rowspan="1" colspan="1">MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>3.0&#x000d7;10<sup>7</sup> MSCs iv at day 0, day 3, day 6<break/>Control group: None specified</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>7</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">48</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">14-02-2020/16-02-2020 to 15-02-2022</td><td align="left" rowspan="1" colspan="1">NA/Not recruiting</td><td align="left" rowspan="1" colspan="1">NCT04273646/<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> ct2/show/NCT04273646</td><td align="left" rowspan="1" colspan="1">Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia</td><td align="left" rowspan="1" colspan="1">UC- MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>4 times of UC-MSCs (0.5&#x000d7;10<sup>6</sup>&#x02005;UC-MSCs&#x000b7;kg<sup>&#x02212;1</sup> body weight iv at day 1, day 3, day 5, day 7)<break/>Control group: None specified</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>8</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">28-02-2020/19-02-2020 to 20-02-2021</td><td align="left" rowspan="1" colspan="1">1/ Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000030300/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showprojen.aspx?proj=50022</td><td align="left" rowspan="1" colspan="1">Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients</td><td align="left" rowspan="1" colspan="1">UC- MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group: MSCs<break/>Control group: None specified</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>9</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">32</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">26-02-2020/14-02-2020 to 31-05-2020</td><td align="left" rowspan="1" colspan="1">NA/Not recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000030224/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showprojen.aspx?proj=49968</td><td align="left" rowspan="1" colspan="1">Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID- 19)</td><td align="left" rowspan="1" colspan="1">MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group 1:<break/>critical group Intervention, injecting MSCs Experimental group 2:<break/>severe group, Intervention, injecting MSCs<break/>Control group 3:<break/>Control of the critical group, intervention, injecting normal saline Control group 4:<break/>Control of the severe group, intervention, injecting normal saline</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>10</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">24-02-2020/17-02-2020 to 17-04-2020</td><td align="left" rowspan="1" colspan="1">0/Not recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000030173/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showprojen.aspx?proj=49229</td><td align="left" rowspan="1" colspan="1">Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration</td><td align="left" rowspan="1" colspan="1">UC- MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group: UC-MSCs<break/>Control group: Convention treatment</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>11</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">24-02-2020/24-02-2020 to 31-05-2020</td><td align="left" rowspan="1" colspan="1">2/Not recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000030138/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=50004</td><td align="left" rowspan="1" colspan="1">Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID- 19)</td><td align="left" rowspan="1" colspan="1">UC- MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Iv injection of UC-MSCs<break/>Control group:<break/>Routine treatment+placebo</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>12</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">23-02-2020/01-02-2020 to 31-08-2020</td><td align="left" rowspan="1" colspan="1">NA/ Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000030116/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=49901</td><td align="left" rowspan="1" colspan="1">Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)</td><td align="left" rowspan="1" colspan="1">UC- MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group: Different stem cell doses<break/>Control group: None specified</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>13</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">40</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">22-02-2020/01-03-2020 to 31-12-2021</td><td align="left" rowspan="1" colspan="1">0/Not recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000030088/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=49902</td><td align="left" rowspan="1" colspan="1">Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID- 19)</td><td align="left" rowspan="1" colspan="1">UC-Whartons Jellys MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Iv injection of Wharton's Jelly MSCs (1&#x000d7;10<sup>6</sup>/kg), cell suspension volume: 40&#x02005;mL<break/>Control group: Iv 40&#x02005;mL saline</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>14</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20-02-2020/06-02-2020 to 05-02-2022</td><td align="left" rowspan="1" colspan="1">NA/ Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000030020/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=49812</td><td align="left" rowspan="1" colspan="1">The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID- 19)</td><td align="left" rowspan="1" colspan="1">MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Case series: MSCs therapy<break/>Control group:<break/>None specified</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>15</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">120</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18-02-2020/30-01-2020 to 31-03-2020</td><td align="left" rowspan="1" colspan="1">1-2/Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000029990/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/sho">http://www.chictr.org.cn/sho</ext-link> wproj.aspx?proj=49674</td><td align="left" rowspan="1" colspan="1">Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID- 19)</td><td align="left" rowspan="1" colspan="1">MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group: MSCs<break/>Control group: Saline</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>16</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">28-02-2020/28-02-2020 to 31-12-2021</td><td align="left" rowspan="1" colspan="1">1-2/Not recruiting</td><td align="left" rowspan="1" colspan="1">NCT04288102/<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/">https://clinicaltrials.gov/ct2/</ext-link> show/NCT04288102</td><td align="left" rowspan="1" colspan="1">Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)</td><td align="left" rowspan="1" colspan="1">MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group: 3 times of MSCs ((body weight&#x02265;70&#x02005;kg, 4.0&#x000d7;10<sup>7</sup> cells per time; body weight &#x0003c;70&#x02005;kg, 3.0&#x000d7;10<sup>7</sup> cells per time) iv at day 0, day 3, day 6).<break/>Control group:<break/>Saline containing 1% human serum albumin (solution of MSCs&#x0ff09;3 times of placebo&#x0ff08;iv at day 0, day 3, day 6&#x0ff09;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>17</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">48</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">24-02-2020/24-02-2020 to 01-02-2021</td><td align="left" rowspan="1" colspan="1">NA/ Recruiting</td><td align="left" rowspan="1" colspan="1">NCT04293692/<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> show/NCT04293692</td><td align="left" rowspan="1" colspan="1">Therapy for Pneumonia Patients Infected by 2019 Novel Coronavirus</td><td align="left" rowspan="1" colspan="1">UC- MSCs</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Participants will receive conventional treatment plus 4 times of 0.5&#x000d7;10<sup>6</sup>&#x02005;UC-MSCs&#x000b7;kg<sup>&#x02212;1</sup> body weight suspended in 100&#x02005;mL saline containing 1% human albumin iv, at day 1, day 3, day 5, day 7. Control group:<break/>Participants will receive conventional treatment plus 4 times of placebo (100&#x02005;mL saline containing 1% human<break/>albumin) iv at day 1, day 3, day 5, day 7.</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Clinical trials based on MSCs-derivatives</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>Date of registration/ Execution time</bold></td><td align="left" rowspan="1" colspan="1"><bold>Study phase/ Recruitment status</bold></td><td align="left" rowspan="1" colspan="1"><bold>ID/ URL</bold></td><td align="left" rowspan="1" colspan="1"><bold>Title</bold></td><td align="left" rowspan="1" colspan="1"><bold>Cell type</bold></td><td align="left" rowspan="1" colspan="1"><bold>Number of total participants/ Intervention or treatment</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>1</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">04-02-2020 /5-02-2020 to 30-04-2021</td><td align="left" rowspan="1" colspan="1">0/ Not<break/>Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000029569/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=49062</td><td align="left" rowspan="1" colspan="1">Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial</td><td align="left" rowspan="1" colspan="1">UC- MSCs CM</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Conventional treatment combined with UC-MSCs CM<break/>Control group: Conventional treatment</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>2</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">19-02-2020/15-02-2020 to 31-07-2020</td><td align="left" rowspan="1" colspan="1">1/ Not Recruiting</td><td align="left" rowspan="1" colspan="1">NCT04276987/<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/">https://clinicaltrials.gov/ct2/</ext-link> show/NCT04276987</td><td align="left" rowspan="1" colspan="1">A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia</td><td align="left" rowspan="1" colspan="1">AT- MSCsExo</td><td align="left" rowspan="1" colspan="1">Experimental group: 5 times aerosol inhalation of MSCs-derived exosomes (2.0&#x000d7;10<sup>8</sup> nano vesicles/3&#x02005; mL at day 1, day 2, day 3, day 4, day 5). Control group: None specified</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>3</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">26</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2020-02-26/28-02-2020 to 31-05-2020</td><td align="left" rowspan="1" colspan="1">0/ Not Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000030261/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showprojen.aspx?proj=49963</td><td align="left" rowspan="1" colspan="1">A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)</td><td align="left" rowspan="1" colspan="1">MSCs Exo</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Aerosol inhalation of exosomes<break/>Control group: Blank</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>4</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">90</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">03-03-2020/31-01-2020 to 31-01-2021</td><td align="left" rowspan="1" colspan="1">NA/ Not Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000030484/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=50263</td><td align="left" rowspan="1" colspan="1">HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)</td><td align="left" rowspan="1" colspan="1">UC- MSCs and Exo</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Group 1: HUMSCs iv, 5&#x000d7;10<sup>7</sup> cells/ time, once / week, twice/course<break/>Group 2:<break/>HUMSCs iv infusion, 5&#x000d7;10<sup>7</sup> cells / time, 1 time / week, 2 times / course, a total of 2 courses; Exosomes: iv<break/>administration, 180&#x02005;mg / time, 1 time / day, 7&#x02005;days / course, 2 courses in total<break/>Control group:<break/>Same amount of placebo (stem cell solvent)</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Clinical trials based on other cell types</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>Date of registration/ Execution time</bold></td><td align="left" rowspan="1" colspan="1"><bold>Study phase/ Recruitment status</bold></td><td align="left" rowspan="1" colspan="1"><bold>ID/ URL</bold></td><td align="left" rowspan="1" colspan="1"><bold>Title</bold></td><td align="left" rowspan="1" colspan="1"><bold>Cell type</bold></td><td align="left" rowspan="1" colspan="1"><bold>Number of participants/ Intervention or treatment</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>1</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">14-02-2020 /20-02-2020 to 20-02-2021</td><td align="left" rowspan="1" colspan="1">0 / Not Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000029812/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=49374</td><td align="left" rowspan="1" colspan="1">Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID- 19)</td><td align="left" rowspan="1" colspan="1">UCBMC</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Conventional treatment followed by iv of UCBMC preparations<break/>Control group: Conventional treatment</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>2</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">05-02-2020 /05-02-2020 to 30-04-2021</td><td align="left" rowspan="1" colspan="1">0 / Recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000029572/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=41760</td><td align="left" rowspan="1" colspan="1">Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled clinical trial</td><td align="left" rowspan="1" colspan="1">UCBMC</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Conventional treatment combined with UCBMC<break/>Control group: Conventional treatment</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>3</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">17-02-2020 /24-02-2020 to 31-12-2024</td><td align="left" rowspan="1" colspan="1">1-2 /Recruiting</td><td align="left" rowspan="1" colspan="1">NCT04276896/<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> show/NCT04276896</td><td align="left" rowspan="1" colspan="1">Function and Safety Study of SARS-CoV-2 Synthetic Minigene Vaccines</td><td align="left" rowspan="1" colspan="1">autologo us LV- DC vaccine or antigen- specific cytotoxic T Cells</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Patients will receive approximately 5&#x000d7;10<sup>6</sup> LV-DC vaccine or 1&#x000d7;10<sup>8</sup> CTLs as a single infusion via sub- cutaneous fluids / Iv injection and may receive additional infusions.<break/>Control group: None specified</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>4</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">13-02-2020 /20-02-2020 to 30-12-2020</td><td align="left" rowspan="1" colspan="1">1 / Recruiting</td><td align="left" rowspan="1" colspan="1">NCT04280224/<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> show/NCT04280224</td><td align="left" rowspan="1" colspan="1">NK Cells Treatment for Novel Coronavirus Pneumonia</td><td align="left" rowspan="1" colspan="1">NK cells</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Conventional treatment plus twice a week of NK cells (0.1-2&#x000d7;10<sup>7</sup>&#x02005;NK cells&#x000b7;kg<sup>&#x02212;1</sup> body weight) Control group: Conventional treatment</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>5</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">06-03-2020/10-04-2020 to 10-11- 2020</td><td align="left" rowspan="1" colspan="1">2 /Not recruiting</td><td align="left" rowspan="1" colspan="1">NCT04299152/<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/s">https://clinicaltrials.gov/ct2/s</ext-link> how/NCT04299152</td><td align="left" rowspan="1" colspan="1">Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</td><td align="left" rowspan="1" colspan="1">CB-SC</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC <italic>in vitro</italic>, and returns the &#x0201c;educated&#x0201d; autologous immune cells to the patient's circulation.<break/>Control group:<break/>Conventional treatment of patients with SARS-CoV-2. Patients will receive the regular treatments by only addressing their symptoms such as reducing fever and cough.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>6</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">90</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">28-02-2020 /01-03-2020 to 17-02-2021</td><td align="left" rowspan="1" colspan="1">0 /Not recruiting</td><td align="left" rowspan="1" colspan="1">ChiCTR2000030088/<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/">http://www.chictr.org.cn/</ext-link> showproj.aspx?proj=49779</td><td align="left" rowspan="1" colspan="1">Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID- 19)</td><td align="left" rowspan="1" colspan="1">CIK and NK</td><td align="left" rowspan="1" colspan="1">Experimental group:<break/>CIK group: UCB CIK cells (1.6&#x000d7;10<sup>8</sup>/kg) were injected twice every other day.<break/>NK group: UCB NK cells (1.6&#x000d7;10<sup>8</sup>/kg) were injected twice every other day.<break/>Control group:<break/>Conventional therapy</td></tr></tbody></table><table-wrap-foot><p>CB-MSCs: Umbilical cord blood derived-mesenchymal stem cells; UCB-NK: Umbilical cord blood derived-natural killer; MenSCs: mesenchymal stem cells derived from menstrual uid; UC-MSCs: umbilical cord derived mesenchymal stem cells; UC-MSCs CM: umbilical cord derived mesenchymal stem cells-conditioned m&#x000e9;dium; AT-MSCs Exo: Adipose tissue xosomes; MSCs Exo: mesenchymal stem cells exosomes; UCBMC: umbilical cord blood derived mononuclear cells; CTL: cytotoxic T cells; LV: lentivirus; DC: dendritic cells; NK: atural killer cells; CB-SC: cord blood stem cells; CIK: Cytokine-induced killer cells; Iv: intravenous.</p></table-wrap-foot></table-wrap><p>Four of the trials will utilise either MSC-derived CM or EVs. Two of these propose aerosol inhalation of MSC-derived EVs, one from adipose-derived MSCs, for which there is no pre-clinical supporting data. Six investigations will utilise other cells including umbilical cord blood derived mononuclear cells (UC-BMC); cytotoxic T cells (CTL); dendritic cells (DC); natural killer cells (NK); cord blood stem cells(CB-SC), or cytokine-induced killer cells (CIK), of which only the latter investigation describes dosing and frequency of injections. As best as we can ascertain, here is no apparent pre-clinical data to support the rationale for any of these approaches.</p></sec><sec id="s8"><title>Ethical issues for considering cell-based approaches for respiratory virus infections</title><p>Activities of health care providers and researchers during an infectious disease outbreak, including clinical trials, are aimed towards finding rapid and effective responses for the treatments of infected patients. These actions need to occur under appropriate ethical guidelines. The WHO has guidelines which embed ethical approaches and considerations within the integrated global alert and response system for epidemics and other public health emergencies [<xref rid="C51" ref-type="bibr">51</xref>]. These are all applicable to cell-based clinical investigations and include assurance that these are scientifically valid and that potential risks are reasonable in relation to anticipated benefits. With respect to safety of MSC administration in critically ill patients including those with ARDS resulting from other etiologies, no significant issues have been described in published articles to date [<xref rid="C51" ref-type="bibr">51</xref>]. With respect to efficacy, there is equipoise at present as only one as yet unpublished exploratory trial of MSC administration has demonstrated beneficial outcomes [<xref rid="C52" ref-type="bibr">52</xref>].</p><p>It is also imperative that the clinical investigations be conducted in a transparent manner according to established precedents for clinical investigations of potential new therapies for critical illnesses [<xref rid="C53" ref-type="bibr">53</xref>]. This includes recognised endpoints, including but not limited to overall mortality, length of ICU and hospital stay and ventilator-free days. We also strongly advocate for utilising clinical samples, obtained as part of appropriate clinical care or for monitoring adverse events following cell administration, to obtain mechanistic information including but not limited to analyses of circulating pro- and anti-inflammatory mediators and inflammatory cell populations. Given the rapidity of the COVID19 spread and the increasing numbers of cell-based therapy investigations, a central coordinating center to expedite congruent trial design and appropriate data dissemination would be of significant benefit.</p><p>A further significant issue is which COVID-19 patient population to target and when to initiate MSC administration. Critically ill patients with ARDS requiring supportive measures including intubation and mechanical ventilation are a logical population. Appreciating that there are other potential therapeutic approaches being considered in this population, it would seem reasonable to target these patients as soon as possible following intubation and mechanical ventilation. Arguments can be made as well for severely infected patients with currently recognised risk factors such as increased age, diabetes and/or cardiovascular disease at potentially higher risk for clinical deterioration. In this instances, emerging data on clinical and laboratory indications, such as level of oxygenation, changes in oxygenation, and elevations in indicators of systemic cytokine storm may be criteria for initiating MSC administration. As these indictors are evolving, we advocate a broad minded approach for considering when to consider MSC use. Whether moderate or mild disease patients should be part of clinical investigation remains less clear. The available pre-clinical data and the safety data from clinical trials in non-viral ARDS best supports potential use. As it is too early to tell whether there will be any downstream respiratory effects in COVID-19 ARDS survivors, this seems a less urgent population to target. Similarly, targeting recovering mild or moderately affected patients to counter as yet unknown downstream effects on the lungs also seems to be a less urgent consideration. Overall, to date there has been a limited understanding of the pathogenesis of COVID-19, which currently hinders the development of an optimal study design</p><p>Whether to utilise genetically modified MSCs is unclear at present. This in part reflects the current lack of understanding as to which action, ie., secreted mediator constitutively or inducibly produced by MSCs, may be most effective in SARS-CoV-2 respiratory infections. This also reflects the lack of clear evidence at present as to whether any other potentially therapeutic agent, for example an IL-6 or IL-1 receptor antagonist that the MSCs could be engineered to produce, also will have proven efficacy. This may change rapidly as current treatment investigations involving these and other agents evolve. Further, as genetically modified cell products require a more a more lengthy regulatory approval, this may not be a strategy of choice to face the current outbreak.</p></sec><sec id="s9"><title>Challenges and perspectives</title><p>The global pandemic of COVID19 repiratory infection has prompted urgent need for novel therapies. Clinical and basic science investigators need to take the lead by promoting and adhering to rigorously designed investigations logically based on available pre-clinical data. The limited available data regarding MSC administration in pre-clinical respiratory disease injury models and current understanding of potential mechanisms of MSC actions in lung injury models can be cautiously and carefully utilised to support rationally designed and conducted clinical investigations. However, more pre-clinical data is necessary, particularly in models of coronavirus-induced lung injuries. While compassionate use of unproven MSC-based therapies may be contemplated in different circumstances, we urge that whenever possible, this take place in the larger context of a clinical investigation. Since the original writing of this review, a number of academic and industry sponsored trials of MSC-based investigations have been initiated globally in addition to the ones in China reviewed. We urge all of these to uphold the highest standards for rationale and approrpaitely designed investigations. Only in these ways can a rationale evidence-based platform for potential therapeutic use of cell-based therapies be developed.</p><p>We must also take strong stance against the stem cell clinic industry which has already begun to offer unproven therapies for COVID19. The ISCT, ISSCR, and a number of other professional and scientific organisations have taken leadership positions in this area [<xref rid="C54" ref-type="bibr">54</xref>&#x02013;<xref rid="C56" ref-type="bibr">56</xref>]. The potential for abuse is high given the desperate circumstances of the COVID-19 pandemic and unauthorised use of unproven therapies is a clear danger.</p></sec></body><back><ack><title>Acknowledgments</title><p>We aknowledge Monica Kurte for performing the bioinformatic analysis of the GEO database. This work was partialy supported by grants from Agencia Nacional de Investigaci&#x000f3;n y Desarrollo, ANID, formely known as CONICYT [FONDEF 2016, IT16I10084].</p></ack><fn-group><fn fn-type="financial-disclosure"><p>Funder: Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica; DOI: http://dx.doi.org/10.13039/501100002848; Grant: FONDEF 2016, IT16I10084.</p></fn><fn fn-type="COI-statement"><p>Conflict of interest: Dr. Cuenca reports grants from CONICYT [FONDEF 2016, IT16I10084], during the conduct of the study; other from Cells for Cells , outside the submitted work; and Research Scientist of Cells for Cells, a University spin-off developing therapies for Osteoarthritis, pulpitis and cardiac failure, and Regenero, a consortium for Chilean regenerative medicine (public and private funding), for skin ulcer and Lupus..</p></fn><fn fn-type="COI-statement"><p>Conflict of interest: Dr. CRUZ has nothing to disclose.</p></fn><fn fn-type="COI-statement"><p>Conflict of interest: Dr. Figueroa reports In addition, Dr. Figueroa has a patent WO/2019/051623 pending and Although I have no financial, commercial or contractual/honoraria link to Cells for Cells; I do sit on their Board, as the Director of the Program of Translational Cell Therapy at Universidad de los Andes, the academic Institution that originated the Consorcio Corfo Regenero and the Cells for Cells biotechnological spin-off. .</p></fn><fn fn-type="COI-statement"><p>Conflict of interest: Dr. Rocco has nothing to disclose.</p></fn><fn fn-type="COI-statement"><p>Conflict of interest: Dr. Weiss reports grants from NIH, grants from Cystic Fibrosis Foundation, grants from US Department of Defense, outside the submitted work.</p></fn><fn fn-type="COI-statement"><p>Conflict of interest: Dr. Khoury reports grants from CONICYT [FONDEF 2016, IT16I10084], during the conduct of the study; other from Cells for Cells , outside the submitted work; In addition, Dr. Khoury has a patent WO2014135924A1 pending, a patent WO2017064670A2 pending, a patent WO2017064672A1 pending, and a patent WO/2019/051623 pending and CSO of Cells for Cells, a University spin-off developing therapies for Osteoarthritis, pulpitis and cardiac failure, and Regenero, a consortium for Chilean regenerative medicine ( public and private funding), for skin ulcer and Lupus..</p></fn></fn-group><ref-list><title>References</title><ref id="C1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title>. <source>N Engl J Med</source>
<year>2020</year>.</mixed-citation></ref><ref id="C2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheahan</surname><given-names>TP</given-names></name>, <name name-style="western"><surname>Sims</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Leist</surname><given-names>SR</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title>. <source>Nat Commun</source>
<year>2020</year>; <volume>11</volume>: <fpage>222</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-13940-6</pub-id><pub-id pub-id-type="pmid">31924756</pub-id></mixed-citation></ref><ref id="C3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>P</given-names></name>, <name name-style="western"><surname>McAuley</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title>. <source>Lancet</source>
<year>2020</year>
<ext-link ext-link-type="uri" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0140673620306280">https://linkinghub.elsevier.com/retrieve/pii/S0140673620306280</ext-link>
<comment>[cited 2020 Mar 19]</comment>.</mixed-citation></ref><ref id="C4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armitage</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>DBA</given-names></name>, <name name-style="western"><surname>Troedson</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mesenchymal stromal cell infusion modulates systemic immunological responses in stable COPD patients: A phase i pilot study</article-title>. <source>Eur Respir J</source>
<year>2018</year>.</mixed-citation></ref><ref id="C5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galipeau</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sens&#x000e9;b&#x000e9;</surname><given-names>L</given-names></name></person-group>
<article-title>Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities</article-title>. <source>Cell Stem Cell</source>
<year>2018</year>.</mixed-citation></ref><ref id="C6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Pulin</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Seo</surname><given-names>MJ</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Intravenous hMSCs Improve Myocardial Infarction in Mice because Cells Embolized in Lung Are Activated to Secrete the Anti-inflammatory Protein TSG-6</article-title>. <source>Cell Stem Cell</source>
<year>2009</year>; <volume>5</volume>: <fpage>54</fpage>&#x02013;<lpage>63</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.stem.2009.05.003</pub-id><pub-id pub-id-type="pmid">19570514</pub-id></mixed-citation></ref><ref id="C7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krasnodembskaya</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37</article-title>. <source>Stem Cells</source>
<year>2010</year>; <volume>28</volume>: <fpage>2229</fpage>&#x02013;<lpage>2238</lpage>. doi:<pub-id pub-id-type="doi">10.1002/stem.544</pub-id><pub-id pub-id-type="pmid">20945332</pub-id></mixed-citation></ref><ref id="C8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mesenchymal Stem Cell Microvesicles Restore Protein Permeability Across Primary Cultures of Injured Human Lung Microvascular Endothelial Cells</article-title>. <source>Stem Cells Transl Med</source>
<year>2018</year>; <volume>7</volume>: <fpage>615</fpage>&#x02013;<lpage>624</lpage>. doi:<pub-id pub-id-type="doi">10.1002/sctm.17-0278</pub-id><pub-id pub-id-type="pmid">29737632</pub-id></mixed-citation></ref><ref id="C9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Court</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Le-Gatt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Luz-Crawford</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitochondrial transfer from MSCs to T cells induces Treg differentiation and restricts inflammatory response</article-title>. <source>EMBO Rep</source>
<year>2020</year>; <volume>21</volume>: <fpage>e48052</fpage>. doi:<pub-id pub-id-type="doi">10.15252/embr.201948052</pub-id><pub-id pub-id-type="pmid">31984629</pub-id></mixed-citation></ref><ref id="C10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Das</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Emin</surname><given-names>MT</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury</article-title>. <source>Nat Med</source>
<year>2012</year>; <volume>18</volume>: <fpage>759</fpage>&#x02013;<lpage>765</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.2736</pub-id><pub-id pub-id-type="pmid">22504485</pub-id></mixed-citation></ref><ref id="C11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liotta</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cosmi</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling</article-title>. <source>Stem Cells</source>
<year>2008</year>; <volume>26</volume>: <fpage>279</fpage>&#x02013;<lpage>289</lpage>. doi:<pub-id pub-id-type="doi">10.1634/stemcells.2007-0454</pub-id><pub-id pub-id-type="pmid">17962701</pub-id></mixed-citation></ref><ref id="C12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waterman</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Tomchuck</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Henkle</surname><given-names>SL</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A New Mesenchymal Stem Cell (MSC) Paradigm : Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype</article-title>. <year>2010</year>; <volume>5</volume>.</mixed-citation></ref><ref id="C13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Krasnodembskaya</surname><given-names>A</given-names></name>, <name name-style="western"><surname>McKenna</surname><given-names>DH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Therapeutic Effects of Human Mesenchymal Stem Cells in <italic>Ex Vivo</italic> Human Lungs Injured with Live Bacteria</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2013</year>; <volume>187</volume>: <fpage>751</fpage>&#x02013;<lpage>760</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201206-0990OC</pub-id><pub-id pub-id-type="pmid">23292883</pub-id></mixed-citation></ref><ref id="C14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monsel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gennai</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Therapeutic Effects of Human Mesenchymal Stem Cell&#x02013;derived Microvesicles in Severe Pneumonia in Mice</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2015</year>; <volume>192</volume>: <fpage>324</fpage>&#x02013;<lpage>336</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201410-1765OC</pub-id><pub-id pub-id-type="pmid">26067592</pub-id></mixed-citation></ref><ref id="C15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice</article-title>. <source>Stem Cell Res Ther</source>
<year>2016</year>; <volume>7</volume>: <fpage>159</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13287-016-0395-z</pub-id><pub-id pub-id-type="pmid">27793190</pub-id></mixed-citation></ref><ref id="C16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polchert</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sobinsky</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Douglas</surname><given-names>G</given-names></name>, <etal>et al.</etal></person-group>
<article-title>IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease</article-title>. <source>Eur J Immunol</source>
<year>2008</year>; <volume>38</volume>: <fpage>1745</fpage>&#x02013;<lpage>1755</lpage>. doi:<pub-id pub-id-type="doi">10.1002/eji.200738129</pub-id><pub-id pub-id-type="pmid">18493986</pub-id></mixed-citation></ref><ref id="C17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malcherek</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>H&#x000fc;ckelhoven</surname><given-names>AG</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mesenchymal stromal cells inhibit proliferation of virus-specific CD8+ T cells</article-title>. <source>Leukemia</source>
<year>2014</year>; <volume>28</volume>: <fpage>2388</fpage>&#x02013;<lpage>2394</lpage>.<pub-id pub-id-type="pmid">25227910</pub-id></mixed-citation></ref><ref id="C18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>T</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Function of Allogeneic Activated V&#x003b3;9V&#x003b4;2 T Lymphocytes In Vitro</article-title>. <source>Biomed Res Int</source>
<year>2015</year>; <volume>2015</volume>: <fpage>317801</fpage>.<pub-id pub-id-type="pmid">25984529</pub-id></mixed-citation></ref><ref id="C19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karlsson</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Samarasinghe</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ball</surname><given-names>LM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses</article-title>. <source>Blood</source>
<year>2008</year>; <volume>112</volume>: <fpage>532</fpage>&#x02013;<lpage>541</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2007-10-119370</pub-id><pub-id pub-id-type="pmid">18445691</pub-id></mixed-citation></ref><ref id="C20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laffey</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Matthay</surname><given-names>MA</given-names></name></person-group>
<article-title>Cell-based therapy for acute respiratory distress syndrome: Biology and potential therapeutic value [Internet]</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2017</year>: <fpage>266</fpage>&#x02013;<lpage>273</lpage>. <ext-link ext-link-type="uri" xlink:href="www.atsjournals.org/doi/10.1164/rccm.201701-0107CP">www.atsjournals.org/doi/10.1164/rccm.201701-0107CP</ext-link>. <comment>[cited 2020 Mar 22]</comment>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201701-0107CP</pub-id><pub-id pub-id-type="pmid">28306336</pub-id></mixed-citation></ref><ref id="C21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Dao Thi</surname><given-names>VL</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Intrinsic Immunity Shapes Viral Resistance of Stem Cells</article-title>. <source>Cell</source>
<year>2018</year>; <volume>172</volume>: <fpage>423</fpage>&#x02013;<lpage>438.e25</lpage>.<pub-id pub-id-type="pmid">29249360</pub-id></mixed-citation></ref><ref id="C22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bailey</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>I-C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>IFITM-Family Proteins: The Cell's First Line of Antiviral Defense</article-title>. <source>Annu Rev Virol</source>
<year>2014</year>; <volume>1</volume>: <fpage>261</fpage>&#x02013;<lpage>283</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-virology-031413-085537</pub-id><pub-id pub-id-type="pmid">25599080</pub-id></mixed-citation></ref><ref id="C23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thanunchai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hongeng</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Thitithanyanont</surname><given-names>A</given-names></name></person-group>
<article-title>Mesenchymal Stromal cells and viral infection</article-title>. <source>Stem Cells Int</source>
<year>2015</year>; <volume>2015</volume>: <fpage>860950</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2015/860950</pub-id><pub-id pub-id-type="pmid">26294919</pub-id></mixed-citation></ref><ref id="C24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khatri</surname><given-names>M</given-names></name>, <name name-style="western"><surname>O'Brien</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Goyal</surname><given-names>SM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Isolation and characterization of chicken lung mesenchymal stromal cells and their susceptibility to avian influenza virus</article-title>. <source>Dev Comp Immunol</source>
<year>2010</year>; <volume>34</volume>: <fpage>474</fpage>&#x02013;<lpage>479</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.dci.2009.12.008</pub-id><pub-id pub-id-type="pmid">20026347</pub-id></mixed-citation></ref><ref id="C25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khatri</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Saif</surname><given-names>YM</given-names></name></person-group>
<article-title>Influenza virus infects bone marrow mesenchymal stromal cells in vitro: Implications for bone marrow transplantation</article-title>. <source>Cell Transplant</source>
<year>2013</year>; <volume>22</volume>: <fpage>461</fpage>&#x02013;<lpage>468</lpage>. doi:<pub-id pub-id-type="doi">10.3727/096368912X656063</pub-id><pub-id pub-id-type="pmid">23006541</pub-id></mixed-citation></ref><ref id="C26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thanunchai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kanrai</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wiboon-ut</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Tropism of avian influenza a (H5N1) virus to mesenchymal stem cells and CD34+ hematopoietic stem cells</article-title>. <source>PLoS One</source>
<year>2013</year>; <volume>8</volume>: <fpage>e81805</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0081805</pub-id><pub-id pub-id-type="pmid">24339969</pub-id></mixed-citation></ref><ref id="C27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Sampayo-Escobar</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Respiratory syncytial virus-infected mesenchymal stem cells regulate immunity via interferon beta and indoleamine-2,3-dioxygenase</article-title>. <source>PLoS</source>
<year>2016</year>; <volume>11</volume>.</mixed-citation></ref><ref id="C28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kleine-Weber</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kr&#x000fc;ger</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells</article-title>. <source>bioRxiv</source>
<year>2020</year>.</mixed-citation></ref><ref id="C29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa</article-title>. <source>Int J Oral Sci</source>
<year>2020</year>; <volume>12</volume>: <fpage>8</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41368-020-0074-x</pub-id><pub-id pub-id-type="pmid">32094336</pub-id></mixed-citation></ref><ref id="C30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziegler</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Allon</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Nyquist</surname><given-names>SK</given-names></name>, <etal>et al.</etal></person-group>
<article-title>SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues</article-title>. <source>SSRN Electron J</source>
<year>2020</year>; <ext-link ext-link-type="uri" xlink:href="www.ssrn.com/abstract=3555145">www.ssrn.com/abstract=3555145</ext-link>
<comment>[cited 2020 Mar 19]</comment></mixed-citation></ref><ref id="C31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group>
<article-title>Strategies to Enhance Mesenchymal Stem Cell-Based Therapies for Acute Respiratory Distress Syndrome</article-title>. <source>Stem Cells Int</source>
<year>2019</year>; <volume>2019</volume>: <fpage>5432134</fpage>.<pub-id pub-id-type="pmid">31885615</pub-id></mixed-citation></ref><ref id="C32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Molina-Molina</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Abdul-Hafez</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>
<year>2008</year>; <volume>295</volume>: <fpage>L178</fpage>&#x02013;<lpage>L185</lpage>. doi:<pub-id pub-id-type="doi">10.1152/ajplung.00009.2008</pub-id><pub-id pub-id-type="pmid">18441099</pub-id></mixed-citation></ref><ref id="C33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mesenchymal stem cells overexpressing angiotensin-converting enzyme 2 rescue lipopolysaccharide-induced lung injury</article-title>. <source>Cell Transplant</source>
<year>2015</year>.</mixed-citation></ref><ref id="C34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Hl</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Qh</given-names></name>, <etal>et al.</etal></person-group>
<article-title>MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS</article-title>. <source>J Cell Physiol</source>
<year>2015</year>; <volume>230</volume>: <fpage>691</fpage>
<lpage>701</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcp.24794</pub-id><pub-id pub-id-type="pmid">25200929</pub-id></mixed-citation></ref><ref id="C35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>FF</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Rocco</surname><given-names>PRM</given-names></name></person-group>
<article-title>Prospects and progress in cell therapy for acute respiratory distress syndrome</article-title>. <source>Expert Opin Biol Ther</source>
<year>2016</year>; <volume>16</volume>: <fpage>1353</fpage>&#x02013;<lpage>1360</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14712598.2016.1218845</pub-id><pub-id pub-id-type="pmid">27487721</pub-id></mixed-citation></ref><ref id="C36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McIntyre</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Moher</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fergusson</surname><given-names>DA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Efficacy of mesenchymal stromal cell therapy for acute lung injury in preclinical animal models: A systematic review</article-title>. <source>PLoS One</source>
<year>2016</year>; <volume>11</volume>: <fpage>e0147170</fpage>.<pub-id pub-id-type="pmid">26821255</pub-id></mixed-citation></ref><ref id="C37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darwish</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Banner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mubareka</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza</article-title>. <source>PLoS One</source>
<year>2013</year>; <volume>8</volume>: <fpage>e71761</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0071761</pub-id><pub-id pub-id-type="pmid">23967240</pub-id></mixed-citation></ref><ref id="C38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gotts</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Abbott</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Matthay</surname><given-names>MA</given-names></name></person-group>
<article-title>Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>
<year>2014</year>; <volume>307</volume>.</mixed-citation></ref><ref id="C39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>MCW</given-names></name>, <name name-style="western"><surname>Kuok</surname><given-names>DIT</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>CYH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2016</year>; <volume>113</volume>: <fpage>3621</fpage>&#x02013;<lpage>3626</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1601911113</pub-id><pub-id pub-id-type="pmid">26976597</pub-id></mixed-citation></ref><ref id="C40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loy</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kuok</surname><given-names>DIT</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>KPY</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating Influenza A(H5N1) Virus-Associated Acute Lung Injury</article-title>. <source>J Infect Dis</source>
<year>2019</year>; <volume>219</volume>: <fpage>186</fpage>&#x02013;<lpage>196</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiy478</pub-id><pub-id pub-id-type="pmid">30085072</pub-id></mixed-citation></ref><ref id="C41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abreu</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Rocco</surname><given-names>PRM</given-names></name></person-group>
<article-title>Extracellular vesicles derived from mesenchymal stromal cells : a therapeutic option in respiratory diseases?</article-title>
<source>Stem Cell Res Ther</source>
<year>2016</year>: <fpage>1</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">26729060</pub-id></mixed-citation></ref><ref id="C42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phelps</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sanati-nezhad</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ungrin</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Review Article Bioprocessing of Mesenchymal Stem Cells and Their Derivatives : Toward Cell-Free Therapeutics</article-title>. <year>2018</year>; <volume>2018</volume>.</mixed-citation></ref><ref id="C43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khatri</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Meulia</surname><given-names>T</given-names></name></person-group>
<article-title>Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model</article-title>. <source>Stem Cell Res Ther</source>
<year>2018</year>; <volume>9</volume>.</mixed-citation></ref><ref id="C44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frieman</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Morrison</surname><given-names>TE</given-names></name>, <etal>et al.</etal></person-group>
<article-title>SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a Type I, II and III Interferon Receptor Independent Mechanism</article-title>. <comment>Gale M, editor</comment>
<source>PLoS Pathog</source>
<year>2010</year>; <volume>6</volume>: <fpage>e1000849</fpage>.<pub-id pub-id-type="pmid">20386712</pub-id></mixed-citation></ref><ref id="C45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The Pathogenicity of 2019 Novel Coronavirus in hACE2 Transgenic Mice</article-title>. <source>bioRxiv</source>
<volume>2020</volume>, <comment>2020.02.07.939389</comment>.</mixed-citation></ref><ref id="C46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Reinfection could not occur in SARS-CoV-2 infected rhesus macaques</article-title>. <source>bioRxiv</source>
<year>2020</year>, <comment>2020.03.13.990226</comment>.</mixed-citation></ref><ref id="C47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leng</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Transplantation of ACE2<sup>&#x02212;</sup> Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia</article-title>. <source>Aging Dis</source>
<fpage>216</fpage>&#x02013;<lpage>228</lpage>.</mixed-citation></ref><ref id="C48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Li L. treatment Corona Virus Disease 2019 &#x02014; Article Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment</article-title>. <source>Engineering</source>
<year>2020</year>.</mixed-citation></ref><ref id="C49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>ZS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)</article-title>. <source>Mil Med Res</source>
<year>2020</year>.</mixed-citation></ref><ref id="C50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthay</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Calfee</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Zhuo</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial</article-title>. <source>Lancet Respir Med</source>
<year>2019</year>; <volume>7</volume>: <fpage>154</fpage>&#x02013;<lpage>162</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(18)30418-1</pub-id><pub-id pub-id-type="pmid">30455077</pub-id></mixed-citation></ref><ref id="C51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Organisation</surname><given-names>WH</given-names></name></person-group>
<article-title>Guidance for managing ethical issues in infectious disease outbreaks</article-title>. <source>World Heal Organ</source>
<year>2016</year>; <volume>62</volume>.</mixed-citation></ref><ref id="C52"><label>52</label><mixed-citation publication-type="standard"><comment>Athersys Provides Update on One-Year ARDS Study Data [Internet]</comment>
<ext-link ext-link-type="uri" xlink:href="www.athersys.com/investors/press-releases/press-release-details/2019/Athersys-Announces-Positive-Results-From-Its-Exploratory-Clinical-Study-of-MultiStem-Cell-Therapy-for-Treatment-of-Acute-Respiratory-Distress-Syndrome-ARDS/default.aspx">www.athersys.com/investors/press-releases/press-release-details/2019/Athersys-Announces-Positive-Results-From-Its-Exploratory-Clinical-Study-of-MultiStem-Cell-Therapy-for-Treatment-of-Acute-Respiratory-Distress-Syndrome-ARDS/default.aspx</ext-link></mixed-citation></ref><ref id="C53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keusch</surname><given-names>GT</given-names></name>, <name name-style="western"><surname>McAdam</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Cuff</surname><given-names>PA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Integrating clinical research into epidemic response: The Ebola experience</article-title>. <source>Integr Clin Res Epidemic Response Ebola Exp</source>
<year>2017</year>. doi:<pub-id pub-id-type="doi">10.17226/24739</pub-id></mixed-citation></ref><ref id="C54"><label>54</label><mixed-citation publication-type="standard"><comment>ISCT Releases Statement on Unproven Stem Cell Treatments for COVID-19 - ISCT [Internet]</comment>
<ext-link ext-link-type="uri" xlink:href="https://isctglobal.org/news/494824/ISCT-Releases-Statement-on-Unproven-Stem-Cell-Treatments-for-COVID-19.htm">https://isctglobal.org/news/494824/ISCT-Releases-Statement-on-Unproven-Stem-Cell-Treatments-for-COVID-19.htm</ext-link>
<comment>[cited 2020 Mar 20]</comment>.</mixed-citation></ref><ref id="C55"><label>55</label><mixed-citation publication-type="standard"><comment>Stem Cells and COVID-19 | Eurostemcell [Internet]</comment>
<ext-link ext-link-type="uri" xlink:href="www.eurostemcell.org/stem-cells-and-covid-19">www.eurostemcell.org/stem-cells-and-covid-19</ext-link>
<comment>[cited 2020 Mar 18]</comment>.</mixed-citation></ref><ref id="C56"><label>56</label><mixed-citation publication-type="standard"><comment>ISSCR Statement Regarding the Marketing of Unproven Stem Cell Treatments for COVID-19 [Internet]. <ext-link ext-link-type="uri" xlink:href="https://www.isscr.org/news-publicationsss/isscr-news-articles/article-listing/2020/03/06/isscr-statement-regarding-the-marketing-of-unproven-stem-cell-treatments-for-covid-19">https://www.isscr.org/news-publicationsss/isscr-news-articles/article-listing/2020/03/06/isscr-statement-regarding-the-marketing-of-unproven-stem-cell-treatments-for-covid-19</ext-link> [cited 2020 Mar 18]</comment>.</mixed-citation></ref></ref-list></back></article>